Ozempic vs. Mounjaro: How the Two GLP-1 Weight-Loss and Diabetes Drugs Compare
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both weekly injections that mimic gut hormones to lower blood sugar and curb appetite, but they differ in how they work, how much weight patients lose in trials, and what each is approved to treat.
Ozempic and Mounjaro are the two names most Americans associate with the new generation of weight-loss injections — but they are not the same drug, and they were not designed for exactly the same job. Both are once-weekly injections that mimic natural gut hormones to lower blood sugar and reduce appetite, yet they work through different biological pathways, carry different FDA approvals, and produced different results in the trials that compared them. Here is what each one is, how they differ, and how doctors and patients typically weigh the choice.
What Ozempic is
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. The FDA first approved it in 2017 as a treatment for adults with type 2 diabetes, to improve blood sugar control. It is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease.
Semaglutide works by imitating glucagon-like peptide-1, a hormone the gut releases after eating. It slows the emptying of the stomach, tells the pancreas to release insulin when blood sugar is high, and signals the brain to reduce hunger — which is why people on it feel full sooner and eat less.
The same active ingredient is sold under other brand names for other uses: Wegovy (a higher-dose semaglutide) is FDA-approved for chronic weight management in adults with obesity, or in adults who are overweight and have a weight-related health condition. Rybelsus is a daily pill form of semaglutide for type 2 diabetes.
What Mounjaro is
Mounjaro is the brand name for tirzepatide, made by Eli Lilly and approved by the FDA in 2022 as a treatment for adults with type 2 diabetes. It is a dual agonist: it mimics two gut hormones, GIP (glucose-dependent insulinotropic polypeptide) as well as GLP-1. That dual action is the central difference between the two drugs.
Tirzepatide works on the same appetite and blood-sugar mechanisms as semaglutide, but the added GIP activity may deepen the effect on appetite and fat metabolism — at least, that is the rationale Lilly put forward, and the head-to-head results that followed suggested it.
Like Ozempic, Mounjaro has a sibling brand for weight management: Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and also for moderate-to-severe obstructive sleep apnea in adults with obesity.
The head-to-head results
The comparison that moved this debate from theory to data was SURMOUNT-5, a trial comparing Zepbound (tirzepatide) directly against Wegovy (semaglutide) in adults with obesity who did not have diabetes. After 72 weeks, participants on the highest tolerated tirzepatide dose lost an average of about 20.2% of their body weight, compared with about 13.7% for semaglutide — a result Lilly announced in late 2024.
In type 2 diabetes, the SURPASS-2 trial compared Mounjaro with Ozempic at their standard diabetes doses and found greater average reductions in blood sugar (A1C) with tirzepatide. Individual results vary widely, and dosing, adherence, and tolerability all shape outcomes — but across the published trials, tirzepatide has generally produced the larger average reductions in both weight and blood sugar.
Side-by-side comparison
| Ozempic (semaglutide) | Mounjaro (tirzepatide) | |
|---|---|---|
| What it is | GLP-1 receptor agonist, approved 2017 for type 2 diabetes | Dual GIP/GLP-1 receptor agonist, approved 2022 for type 2 diabetes |
| Who gets it | Adults with type 2 diabetes; its sibling Wegovy is for chronic weight management in qualifying adults | Adults with type 2 diabetes; its sibling Zepbound is for chronic weight management in qualifying adults |
| Costs | High U.S. list prices, roughly $1,000 per month; coverage varies by insurer and indication, and list prices change over time | High U.S. list prices, roughly $1,000 per month; coverage varies by insurer and indication, and list prices change over time |
| Pros | Longer track record and more long-term safety data; established cardiovascular benefit in type 2 diabetes | Greater average weight loss and A1C reduction in head-to-head trials; dual-hormone mechanism |
| Cons | Lower average weight loss than tirzepatide in trials; like all GLP-1 drugs, commonly causes nausea and other gastrointestinal effects | Newer, with less long-term safety data; similar gastrointestinal side effects; both carry warnings for pancreatitis and a boxed warning about thyroid tumors observed in animals |
The verdict: which one, and for whom
Choose the semaglutide path (Ozempic, or Wegovy for weight management) if a long track record matters most to you: it has been on the market since 2017, has the deepest long-term safety record in its class, and carries an established cardiovascular benefit for people with type 2 diabetes and heart disease. It is also the option your insurance is more likely to have already built coverage rules around.
Choose the tirzepatide path (Mounjaro, or Zepbound for weight management) if the deciding factor is the trial evidence on magnitude: head-to-head studies found greater average weight loss and greater average blood-sugar reduction with tirzepatide. Patients who did not reach their goals on a GLP-1 alone sometimes move to a dual agonist under their doctor’s supervision.
Either way, both drugs require a prescription, both are weekly injections with gradual dose increases, both can cause nausea, vomiting, or diarrhea (especially when starting or raising the dose), and both are meant to be used alongside diet and exercise — they are not standalone shortcuts. Weight tends to return if the medication is stopped, and neither is considered appropriate for casual cosmetic weight loss. The right choice depends on your medical history, what your insurance covers, and a conversation with your own doctor, who can weigh factors like heart disease risk and side-effect tolerance that no comparison table can settle.
Explainer based on program rules published by the FDA (Ozempic, Wegovy, Mounjaro, and Zepbound prescribing information), Novo Nordisk, and Eli Lilly, including published results from the SURMOUNT-5 and SURPASS-2 trials.
